INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

Core Viewpoint - Anavex Life Sciences Corp. is under investigation for potential securities fraud and unlawful business practices following a negative trend vote on its Marketing Authorisation Application for blarcamesine, leading to a significant drop in stock price [1][2]. Group 1: Company Overview - Anavex Life Sciences Corp. (NASDAQ: AVXL) is facing scrutiny from Pomerantz LLP regarding possible securities fraud or other unlawful business practices [1]. - The company announced a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) concerning its drug blarcamesine [2]. Group 2: Market Reaction - Following the announcement of the negative trend vote, Anavex's stock price decreased by $2.05 per share, representing a decline of 35.94%, closing at $3.65 per share on November 14, 2025 [2].